Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.48 USD | -0.31% | -6.43% | -26.86% |
May. 20 | HC Wainwright Starts Coverage on Prime Medicine With Buy Rating, $10 Price Target | MT |
May. 17 | North American Morning Briefing : The "Everything -2- | DJ |
Financials (USD)
Sales 2024 * | 4.44M | Sales 2025 * | 3.65M | Capitalization | 749M |
---|---|---|---|---|---|
Net income 2024 * | -193M | Net income 2025 * | -215M | EV / Sales 2024 * | 151 x |
Net cash position 2024 * | 76.98M | Net cash position 2025 * | 205M | EV / Sales 2025 * | 149 x |
P/E ratio 2024 * |
-3.86
x | P/E ratio 2025 * |
-4.29
x | Employees | 234 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 73.52% |
Latest transcript on Prime Medicine, Inc.
1 day | -0.31% | ||
1 week | -6.43% | ||
1 month | +22.96% | ||
3 months | -25.86% | ||
6 months | -19.60% | ||
Current year | -26.86% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 70 | 20-06-30 | |
Allan Reine
DFI | Director of Finance/CFO | 49 | Jan. 16 |
Chief Operating Officer | 52 | 22-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 64 | 21-11-30 | |
Robert Nelsen
BRD | Director/Board Member | 60 | 20-08-31 |
Michael Kelly
BRD | Director/Board Member | 67 | 21-10-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.71% | 2 M€ | -25.75% | ||
0.00% | 9 M€ | +9.86% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 6.48 | -0.31% | 1,042,303 |
24-05-30 | 6.5 | -0.61% | 1,115,505 |
24-05-29 | 6.54 | +0.62% | 834,890 |
24-05-28 | 6.5 | -6.14% | 1,258,210 |
24-05-24 | 6.925 | -0.22% | 543,204 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.86% | 749M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- PRME Stock